GTHX - G1 Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

188.4M

Cash

65.19M

Avg Qtr Burn

-4.546M

Short % of Float

16.05%

Insider Ownership

11.04%

Institutional Own.

33.86%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
COSELA™ Trilaciclib (G1T28) (CDK4/6 inhibitor) Details Cancer, Solid tumor/s, Small cell lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Breast cancer, Cancer, Triple-negative breast cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) + avelumab Details Solid tumor/s, Cancer, Bladder cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) + Trodelvy® (sacituzumab govitecan-hziy) (ADC) Details Solid tumor/s, Cancer, Metastatic breast cancer, Triple-negative breast cancer , Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rintodestrant + palbociclib Details Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.